Scarica l'app Stockscreener
2.61
2.35%
0.06
Dopo l'orario di chiusura:
2.51
-0.10
-3.83%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MXCT Giù?
Forum
Previsione
Maxcyte Inc Borsa (MXCT) Ultime notizie
MaxCyte Announces Change in Major Holdings by BlackRock - TipRanks
Cooley Advises Cell Therapy Biz On London Market Exit - Law360
MaxCyte intends to delist from London's AIM to enhance liquidity - MarketScreener
MaxCyte to Delist from AIM, Focus on Nasdaq - TipRanks
MaxCyte Announces Change in Voting Rights Structure - TipRanks
MaxCyte stock plunges to 52-week low of $2.25 amid market challenges By Investing.com - Investing.com South Africa
MaxCyte stock plunges to 52-week low of $2.25 amid market challenges - Investing.com India
MaxCyte sets date for Q1 2025 financial results reveal By Investing.com - Investing.com South Africa
MaxCyte sets date for Q1 2025 financial results reveal - Investing.com
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025 - The Manila Times
MaxCyte to Announce Q1 2025 Financial Results - TipRanks
MaxCyte Sets Q1 Earnings Date: Key Financial Updates Coming May 7 - Stock Titan
Insider Buyers Lose US$201k As MaxCyte Sheds UK£32m - simplywall.st
Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT) - Yahoo Finance
With 66% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big guns - Yahoo Finance
Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround - Yahoo Finance
MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know - MSN
MaxCyte Inc (MXCT) Volatility Hits 6.24% – Here Is What You Should Do - stocksregister.com
MaxCyte Stock Hits 52-Week Low at $2.62 Amid Market Challenges - Investing.com Australia
MaxCyte Stock Hits 52-Week Low at $2.62 Amid Market Challenges By Investing.com - Investing.com South Africa
MaxCyte Expands Capital with New Stock Issuance - TipRanks
Charles Schwab Investment Management Inc. Decreases Stake in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte stock plunges to 52-week low, touches $2.75 - Investing.com
MaxCyte CFO completes RSU vesting and tax-related sale By Investing.com - Investing.com Australia
MaxCyte CFO completes RSU vesting and tax-related sale - Investing.com India
MaxCyte Announces CFO’s RSU Vesting and Share Sale - TipRanks
MaxCyte Announces Change in Major Shareholder Voting Rights - TipRanks
Bank of New York Mellon Corp Reduces Stake in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte executives receive equity incentives By Investing.com - Investing.com South Africa
MaxCyte executives receive equity incentives - Investing.com India
MaxCyte Awards Stock Options and Units to Executives - TipRanks
Maxcyte CFO Douglas Swirsky sells $22,061 in common stock By Investing.com - Investing.com Australia
MaxCyte chief commercial officer Ali Soleymannezhad sells $3,850 in stock By Investing.com - Investing.com Australia
MaxCyte chief commercial officer Ali Soleymannezhad sells $3,850 in stock - Investing.com India
Maxcyte general counsel David Sandoval sells $1,122 in stock - Investing.com
Maxcyte CFO Douglas Swirsky sells $22,061 in common stock - Investing.com
BlackRock Increases Stake in MaxCyte to 7.71% - TipRanks
1.01%
0.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):